Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4 and 7 bp deletion in exon4.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IRF2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Interferon Regulatory Factor 2 (IRF2) also known as IRF-2 plays an important role in cellular processes like modulation of immune responses and regulation of gene expression. It has a molecular mass of approximately 39 kDa. IRF2 is expressed across various tissues including the immune system cells fibroblasts and epithelial cells. It can function as both a transcriptional activator and repressor depending on the context and specific gene targets.
Biological function summary
IRF2 regulates immune responses by controlling the expression of interferon (IFN) responsive genes. It acts independently and as part of transcriptional complexes binding to specific DNA sequences within target genes. Its action prevents excessive activation of immune responses maintaining a balanced immune system. IRF2 also influences cell cycle regulation contributing to its role in cell growth and differentiation.
Pathways
And several cellular communication networks IRF2 is a central figure in the interferon signaling pathway interacting with other members of the IRF family like IRF1 and IRF3. These interactions help propagate signals necessary for effective immune responses. In conjunction with the JAK-STAT pathway IRF2 modulates expressions that control antiviral responses and cellular proliferation showing its critical placement in immune response regulation.
IRF2's dysregulation has associations with cancer and autoimmune diseases. Overexpression of IRF2 is linked to certain cancers providing cells with growth advantages and resistance to apoptosis commonly in concert with proteins like STAT1. In autoimmune diseases IRF2 impacts inflammatory responses with aberrant regulation contributing to conditions like systemic lupus erythematosus. Its involvement highlights the complex nature of immune regulation and potential for targeted therapy interventions.
